{
    "root": "2f25cdcd-42eb-73ea-e063-6294a90ad229",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ELIQUIS",
    "value": "20250227",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "APIXABAN",
            "code": "3Z9Y7UWC1J"
        }
    ],
    "indications": "ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5)",
    "contraindications": "Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation: The recommended dose is 5 mg orally twice daily. (2.1) In patients with at least 2 of the following characteristics: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily. (2.1) Prophylaxis of DVT following hip or knee replacement surgery: The recommended dose is 2.5 mg orally twice daily. (2.1) Treatment of DVT and PE: The recommended dose is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily. (2.1) Reduction in the risk of recurrent DVT and PE following initial therapy: The recommended dose is 2.5 mg taken orally twice daily. (2.1)",
    "warningsAndPrecautions": "ELIQUIS (apixaban) tablets are available as listed in the table below.\n                              Pink, oval, biconvex, Debossed with “894” on one side and “5” on the other side\n                              \n                              NDC: 70518-1861-00\n                              NDC: 70518-1861-01\n                              NDC: 70518-1861-02\n                              PACKAGING: 30 in 1 BLISTER PACK\n                              PACKAGING: 60 in 1 BOTTLE, PLASTIC\n                              PACKAGING: 180 in 1 BOTTLE, PLASTIC\n                              \n                              Storage and Handling\n                              Store at 20°C to 25°C (68°F-77°F); excursions permitted between 15°C and 30°C (59°F-86°F) [see USP Controlled Room Temperature].\n                              \n                              Repackaged and Distributed By:\n                              Remedy Repack, Inc.\n                              625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "ELIQUIS is contraindicated in patients with the following conditions:\n                  \n                     Active pathological bleeding \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.2) and \n         \n   \n    Adverse Reactions (6.1)]\n        \n  \n   \n                     \n                     Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) \n        \n  \n   [see \n         \n   \n    Adverse Reactions (6.1)]"
}